COVID-19 vaccines
More support easing vaccine patent rules, but hurdles remain
Several world leaders Thursday praised the U.S. call to remove patent protections on COVID-19 vaccines to help poor countries obtain shots. But the proposal faces a multitude of hurdles, including resistance from the pharmaceutical industry.
Nor is it clear what effect such a step might have on the campaign to vanquish the outbreak.
Activists and humanitarian institutions cheered after the U.S. reversed course Wednesday and called for a waiver of intellectual property protections on the vaccine. The decision ultimately is up to the 164-member World Trade Organization, and if just one country votes against a waiver, the proposal will fail.
The Biden administration announcement made the U.S. the first country in the developed world with big vaccine manufacturing to publicly support the waiver idea floated by India and South Africa in October. On Thursday, French President Emmanuel Macron embraced it as well.
“I completely favor this opening up of the intellectual property,” Macron said at a vaccine center.
However, like many pharmaceutical companies, Macron insisted that a waiver would not solve the problem of access to vaccines. He said manufacturers in places like Africa are not now equipped to make COVID-19 vaccines, so donations of shots from wealthier countries should be given priority instead.
Pfizer, Moderna, Johnson & Johnson and AstraZeneca — all companies with licensed COVID-19 vaccines — had no immediate comment, though Moderna has long said it will not pursue rivals for patent infringement during the pandemic.
Also read: US tribe shares vaccine with relatives, neighbors in Canada
U.S. Secretary of State Antony Blinken underscored the urgency of moving fast now.
“On the current trajectory, if we don’t do more, if the entire world doesn’t do more, the world won’t be vaccinated until 2024,” he said in an interview with NBC while visiting Ukraine.
India, as expected, welcomed the move. Australian Prime Minister Scott Morrison called the U.S. position “great news.”
Italian Foreign Minister Luigi Di Maio wrote on Facebook that the U.S. announcement was “a very important signal” and that the world needs “free access” to vaccine patents. But Italian Premier Mario Draghi was more circumspect.
Russian President Vladimir Putin said his country would support it. U.N. Secretary-General Antonio Guterres welcomed the U.S. decision too.
But German Chancellor Angela Merkel’s office spoke out against it, saying: “The protection of intellectual property is a source of innovation and must remain so in the future.”
Also read: US support behind vaccine patent waiver ‘monumental moment’ in Covid fight: WHO
A Merkel spokeswoman, speaking on customary condition of anonymity, said Germany is focused instead on how to increase vaccine manufacturers’ production capacity.
In Brazil, one of the deadliest COVID-19 hot spots in the world, Health Minister Marcelo Queiroga said he fears that the country does not have the means to produce vaccines and that the lifting of patent protections could interfere with Brazil’s efforts to buy doses from pharmaceutical companies.
In closed-door talks at the WTO in recent months, Australia, Britain, Canada, the European Union, Japan, Norway, Singapore and the United States opposed the waiver idea, according to a Geneva-based trade official who was not authorized the discuss the matter and spoke on condition of anonymity.
Some 80 countries, mostly developing ones, have supported the proposal, the official said. China and Russia — two other major COVID-19 vaccine makers — didn’t express a position but were open to further discussion, the official said.
EU Commission President Ursula von der Leyen said the 27-nation bloc is ready to talk about the idea, but she remained noncommittal and emphasized that the EU has been exporting vaccines widely — while the U.S. has not.
EU leaders said the bloc may discuss the matter at a summit that starts Friday.
Also read: US backs waiving intellectual property rules on vaccines
The pharmaceutical industry has argued that a waiver will do more harm than good in the long run.
Easing patent protections would eat into their profits, potentially reducing the incentives that push companies to innovate and make the kind of tremendous leaps they did with the COVID-19 vaccines, which have been churned out at a blistering, unprecedented pace.
The industry has contended, too, that production of the vaccines is complicated and can’t be ramped up simply by easing patent rights. Instead, it has said that reducing snarls in supply chains and shortages of ingredients is a more pressing issue.
The industry has insisted that a faster solution would be for rich countries to share their vaccine stockpiles with poorer ones.
“A waiver is the simple but the wrong answer to what is a complex problem,” said the International Federation of Pharmaceutical Manufacturers and Associations. “Waiving patents of COVID-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis.”
Intellectual property law expert Shyam Balganesh, a professor at Columbia University, said a waiver would only go so far because of bottlenecks in the manufacturing and distribution of vaccines.
Also read: EU medicine regulator starts rolling review of Sinovac COVID-19 vaccine
Backers of the waiver say that expanded production by the big pharmaceutical companies and donations from richer countries to poor ones won’t be enough, and that there are manufacturers standing by that could make the vaccines if given the blueprints.
“A waiver of patents for #COVID19 vaccines & medicines could change the game for Africa, unlocking millions more vaccine doses & saving countless lives,” World Health Organization Africa chief Matshidiso Moeti tweeted.
Just over 20 million vaccine doses have been administered across the African continent, which has 1.3 billion people.
There is precedent: In 2003, WTO members agreed to waive patent rights and allow poorer countries to import generic treatments for the AIDS virus, malaria and tuberculosis.
“We believe that when the history of this pandemic is written, history will remember the move by the U.S. government as doing the right thing at the right time,” Africa CDC Director John Nkengasong said.
Deal with Russia soon over Covid vaccine: Health Minister
Reaffirming that the government is making all-out efforts to collect Covid-19 vaccines from different sources, Health Minister Zahid Maleque on Thursday said they are now at the stage of signing a deal with Russia to procure Sputnik-V vaccine.
Speaking at a virtual discussion arranged by Bangladesh Private Medical College Association, he said they are also trying to procure the Oxford–AstraZeneca vaccine from other countries besides India.
Also Read: Bangladesh seeks immediate delivery of 4 mn vaccine doses from US: FM
“We’ve been using the AstraZeneca vaccine as we had placed an order for 3 crore doses of it. We’ve got only 70 lakh jabs in addition to 30 lakh that came as a gift…but now we don’t have that much vaccine in our stock and whatever is left will be given as the second dose,” the minister said
He said the Prime Minister, Health Ministry, Foreign Ministry and other relevant ministries are making joint efforts to procure vaccines from other sources.
“We’ve already made a huge progress in discussions with Russia over procuring its vaccine … now we’re at the stage of signing a deal in this regard,” Maleque said.
He said they are also in talks with China to have Sinopharm’s Covid vaccine. “They informed us that five lakh of doses will arrive in Bangladesh by May 12. We’ve also sent a letter to them seeking more vaccine doses.”
The minister said the Chinese government is now assessing the possibility of vaccine export to Bangladesh.
Also Read: Serum to return money if it fails to provide vaccine: Finance Minister
“So, we’re making all-out efforts to collect the vaccine. Even, we’re trying to have AstraZeneca’s vaccine from other countries as it’s being manufactured in different countries. So, every effort is there to bring vaccines. We hope our efforts will yield good results, and we may be able to give you good news over the vaccine very soon,” he said.
The minister also said they will encourage the private sector if it tries to manufacture vaccines in Bangladesh. “If anyone can produce vaccines, we’ll provide all-out support, and it’s my commitment.”
Speaking at the programme, State Minister for Disaster Management and Relief Dr Enamur Rahman said there is no alternative to vaccinating people to control the coronavirus.
He said the government is working sincerely on procuring vaccines from Russia, China and other sources as there has been a crisis of AstraZeneca’s jabs in India.
Also Read: Efforts intensified to get Oxford-AstraZeneca vaccines from US: FM
Besides, he said, Bangladesh Medical Research Council (BMRC) has already approved local company Globe Biotech’s 'Bangovax' vaccine. “We hope we’ll be able to vaccinate most of our people by collecting the vaccines within a few months.”
He said all the pandemics that emerged in the world earlier had been brought under control through vaccinations. “We hope we’ll be able to control the corona pandemic by vaccinating our 60-80 percent people.”
India hits another grim record as it scrambles oxygen supply
Infections in India hit another grim daily record on Thursday as demand for medical oxygen jumped seven-fold and the government denied reports that it was slow in distributing life-saving supplies from abroad.
The number of new confirmed cases breached 400,000 for the second time since the devastating surge began last month. The 412,262 cases pushed India’s tally to more than 21 million. The Health Ministry also reported 3,980 deaths in the last 24 hours, bringing the total to 230,168. Experts believe both figures are an undercount.
Also Read:India's virus surge damages Modi's image of competence
Eleven COVID-19 patients died as the pressure in the oxygen line dropped suddenly in a government medical college hospital in Chengalpet town in southern India on Wednesday night, possibly because of a faulty valve, The Times of India newspaper reported.
Hospital authorities said they had repaired the pipeline last week, but the consumption of oxygen doubled since then, the daily said.
Demand for hospital oxygen has increased seven times since last month, a government official said, as India scrambles to set up large oxygen plants and transport cryogenic tankers, cylinders and liquid oxygen. India created a sea bridge on Tuesday to ferry oxygen tankers from Bahrain and Kuwait in the Persian Gulf, officials said.
Most hospitals in India aren’t equipped with independent plants that generate oxygen directly for patients, As a result, hospitals typically rely on liquid oxygen, which can be stored in cylinders and transported in cryogenic tankers. But amid the surge, supplies in hard-hit places like New Delhi are running critically short.
Health Minister Harsh Vardhan said India has enough liquid oxygen but it’s facing capacity constraint in moving it. Most oxygen is produced in the eastern parts of India while the demand has risen in northern and western parts.
Also Read:Indian government faces lockdown calls, contempt charges
K. Vijay Raghvan, a principal scientific adviser to the government, said this phase of the pandemic was “a very critical time for the country.”
The United States, Britain, Germany and several other nations are rushing therapeutics, rapid virus tests and oxygen, along with materials needed to boost domestic production of COVID-19 vaccines to ease pressure on the fragile health infrastructure.
India’s vaccine production is expected to get a boost with the United States supporting a waiver of intellectual property protections for COVID-19 vaccines.
Vaccine components from the U.S. that had arrived in India will enable the manufacturing of 20 million doses of the AstraZeneca vaccine, said Daniel B. Smith, the most senior diplomat at the embassy in New Delhi.
Last month, Adar Poonawalla, chief executive officer of the Serum Institute of India, the world’s biggest vaccine maker, appealed to President Joe Biden to lift the embargo on U.S. export of raw materials, which, he said, was affecting its production of COVID-19 shots.
Also Read:India reports over 380,000 new cases, tally at 20,665,148
The government meanwhile described as “totally misleading” Indian media reports that it took seven days for it to come up with a procedure for distributing urgent medical supplies that started arriving on April 25.
The statement sad that a streamlined and systematic mechanism for allocation of the supplies received by India has been put in place for effective distribution. The Indian Red Cross Society is involved in distributing supplies from abroad, it said.
US backs waiving intellectual property rules on vaccines
The Biden administration is throwing its support behind efforts to waive intellectual property protections for COVID-19 vaccines in an effort to speed the end of the pandemic.
United States Trade Representative Katherine Tai announced the government’s position in a Wednesday statement, amid World Trade Organization talks over easing global trade rules to enable more countries to produce more of the life-saving vaccines.
“The Administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines,” Tai said in the statement.
But she cautioned that it would take time to reach the required global “consensus” to waive the protections under WTO rules, and U.S. officials said it would not have an immediate effect on the global supply of COVID-19 shots.
“This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures,” said Tai. “The Administration’s aim is to get as many safe and effective vaccines to as many people as fast as possible.”
Also read: PVA bats for suspension of intellectual property rights on Covid jabs
Tai’s announcement comes hours after WTO Director-General Ngozi Okonjo-Iweala spoke to a closed-door meeting of ambassadors from developing and developed countries that have been wrangling over the issue, but agree on the need for wider access to COVID-19 treatments, WTO spokesman Keith Rockwell said.
The WTO’s General Council — made up of ambassadors — was taking up the pivotal issue of a temporary waiver for intellectual property protections on COVID-19 vaccines and other tools, which South Africa and India first proposed in October. The idea has gained support in the developing world and among some progressive lawmakers in the West.
Rockwell said a WTO panel on intellectual property was set to take up the waiver proposal again at a “tentative” meeting later this month, before a formal meeting June 8-9.
No consensus -- which is required under WTO rules -- was expected to emerge from the ambassadors’ two-day meeting Wednesday and Thursday. But Rockwell pointed to a change in tone after months of wrangling.
Also read: Senators to Biden: Waive vaccine intellectual property rules
“I would say that the discussion was far more constructive, pragmatic. It was less emotive and less finger pointing than it had been in the past,” Rockwell said, citing a surge in cases in places like India. “I think that this feeling of everyone-being-in-it-together was being expressed in a way that I had not heard to this point.”
Authors of the proposal, which has faced resistance from many countries with influential pharmaceutical and biotech industries, have been revising it in hopes of making it more palatable.
Okonjo-Iweala, in remarks posted on the WTO website, said it was “incumbent on us to move quickly to put the revised text on the table, but also to begin and undertake text-based negotiations.”
“I am firmly convinced that once we can sit down with an actual text in front of us, we shall find a pragmatic way forward,” that is “acceptable to all sides,” she said.
Co-sponsors of the idea were shuttling between different diplomatic missions to make their case, according to a Geneva trade official who was not authorized to speak publicly on the matter. A deadlock persists, and opposing sides remain far apart, the official said.
Also read: Covid-19 vaccines: Ex-leaders, Nobel laureates urge Biden to waive intellectual property rules
The argument, part of a long-running debate about intellectual property protections, centers on lifting patents, copyrights and protections for industrial design and confidential information to help expand the production and deployment of vaccines during supply shortages. The aim is to suspend the rules for several years, just long enough to beat down the pandemic.
The issue has become more pressing with a surge in cases in India, the world’s second-most populous country and a key producer of vaccines — including one for COVID-19 that relies on technology from Oxford University and British-Swedish pharmaceutical maker AstraZeneca.
Proponents, including WHO Director-General Tedros Adhanom Ghebreyesus, note that such waivers are part of the WTO toolbox and insist there’s no better time to use them than during the once-in-a-century pandemic that has taken 3.2 million lives, infected more than 437 million people and devastated economies.
More than 100 countries have come out in support of the proposal, and a group of 110 members of Congress — all fellow Democrats of Biden — sent him a letter last month that called on him to support the waiver.
Opponents say a waiver would be no panacea. They insist that production of coronavirus vaccines is complex and simply can’t be ramped up by easing intellectual property, and say lifting protections could hurt future innovation.
Covid’s daily death toll in Bangladesh falls to 50
Bangladesh recorded 50 more deaths from Covid-19 in 24 hours until Wednesday morning, showing a marked fall in the fatality rate.
With the new death figure, the mortality from the Coronavirus rose to 11,755, according to a handout issued by the Directorate General of Health Services (DGHS).
The number of Covid deaths came down to 50 after over a month as the country saw 50 deaths on April 1 and it had kept rising since then.
Health authorities recorded 1,742 new cases during the period.
The latest figure pushed up the caseload to 7,67,338.
However, the infection rate fell to 8.59 percent from Tuesday’s 8.71 percent while the fatality rate remained static at 1.53 percent.
The body count soared to over 100 during April 16-19 and on April 25 but the daily fatalities have been falling gradually since then.
In the last 24 hours, 427 labs across the country tested 20,284 samples.
Among the recent deaths, 32 were men while 18 were women.
Besides 3,433 patients recovered from Covid-19 during the last 24 hours, putting the recovery rate at 91.02%.
Also Read: Serum to return money if fails to provide vaccine: Finance Minister
Vaccination Drive
Bangladesh kicked off its vaccination drive on February 7 with Oxford-AstraZeneca doses it purchased from the Serum Institute of India Pvt Ltd.
Bangladesh signed an agreement with Serum for 30 million doses. But a record number of cases in India has made the delivery of the doses uncertain.
The administering of the first dose has remained suspended since April 26, and no one in the country has received the second dose in the last 48 hours.
However, DGHS DG Prof ABM Khurshid Alam assured that Bangladesh will get 2.1 million doses of vaccines by early May.
In the last 24 hours, 38 people have received the first dose and 83,540 have received the second dose of Covid vaccine, a figure which is exactly the same of yesterday, according to the DGHS handout.
So far, a total of 72,48,829 people received vaccines where 31,06709 people managed to complete their second dose.
Also Read: Covid vaccine stock running out: DGHS
Vaccine stock dwindling
The DGHS on Wednesday said the stock of the Covid-19 vaccine is running out in Bangladesh as there are only 14 lakh jabs in government hands with no sign in sight to get a fresh consignment of it from India.
Speaking at a virtual press briefing, DGHS spokesperson Dr Robed Amin said, “We had around one crore and two lakh vaccines in our hands…around 88 lakh jabs have already been administered as the first and second doses. Now we’ve some 14 lakh doses in stock.”
He said there will be a vaccine crisis if a fresh consignment does not arrive in the country before the existing stock is exhausted.
Also Read: New variant may be behind Covid surge in Bangladesh: Experts
Drive intensified to get vaccines from US
Foreign Minister Dr AK Abdul Momen on Wednesday said the government has intensified its efforts to have vaccine jabs from the United States (US) as it will share up to 60 million doses of its Oxford-AstraZeneca Covid-19 vaccine with other countries.
Lockdown extended
The government has issued a notification extending the ongoing lockdown until May 16 with six fresh directives alongside the existing ones to contain the spread of Covid-19.
According to the notification issued by the Cabinet Division, the officials of all government, semi-government autonomous and private organisations, banks and financial institutions have been asked to remain at their respective workstations during the upcoming Eid-ul-Fitr holidays.
Shops and shopping malls will remain open from 10 am to 8 pm maintaining health guidelines. If any kind of deviation and violation are seen, the shopping malls and shops will be closed instantly, says the notification.
Inter-district transport services will remain closed while only intra-district transport services will operate ensuring health guidelines from Thursday.
However, launch and train services will remain off.
Intensify efforts to procure vaccines for alternative sources: BNP
Voicing concerns over the suspension of administering the first dose of Covid vaccine in Bangladesh, the BNP standing committee has urged the government to intensify its efforts for collecting the jabs from alternative sources.
“Our standing committee is worried over the vaccine crisis and the suspension of the vaccination programme. The government couldn’t collect the necessary vaccine doses due to its irresponsibility and incompetence,” BNP Secretary General Mirza Fakhrul Islam Alamgir said on Sunday.
Speaking at a virtual press conference on the outcomes of BNP standing committee’s meeting held on Saturday, he said the government has also failed to take the right decision on the vaccine import as it has become “isolated from people”.
Also read: Govt doing business in Covid’s name: BNP
“Corruption is the main reason behind such a vaccine crisis. They’ve taken a wrong decision on procuring the vaccine from a single source in India through a corrupt company owned by a leader of their party,” the BNP leader observed.
Fakhrul said their party and the country’s health experts had warned the government of the consequences of procuring the vaccine from a single source, but it did not change its stance.
“They (govt) didn’t look for an alternative source of the corona vaccine as it always thinks of benefits of its leaders, not people…the government is running the country with some mafias and the mafias are playing the important role in making decisions and running the country,” he alleged.
Also read: Engaging single organisation in buying vaccines a ‘suicidal’ move: BNP
The BNP leader said there is no alternative to installing a pro-people government through a credible election under a non-party administration to get rid of the current situation of the country.
He said the Serum Institute of India has violated the agreement on providing three crores of vaccine to Bangladesh by stopping the supply after only giving 70 lakh jabs, but the government did not raise voice against it.
Fakhrul said their standing committee urged the government to take necessary steps for increasing oxygen production in the country alongside immediately procuring the vaccine from alternative sources.
Covid-19: Bangladesh logs 69 more deaths, 1,359 new cases
The health authorities reported 69 more coronavirus-related deaths in 24 hours until Sunday morning, taking the death toll to 11,569, as Bangladesh grapples to tackle the second wave of the pandemic.
Besides, 1,359 new cases were detected after examining 14,158 samples, the lowest number of tests since April 18, according to government data.
The health authorities have so far tested 5,498,979 samples. There has been a steady decline in the number of tests since April 28. New cases have been on the wane since April 26 but fell dramatically since April 28, data available on corona.gov.bd show.
However, the daily infection rate fell to 9.6 percent from Saturday’s 9.61 percent while the fatality rate rose to 1.52 percent from 1.51 percent a day before, said the Directorate General of Health Services (DGHS).
With the new cases, the country’s total Covid-19 caseload now stands at 761,943, the DGHS handout said.
Bangladesh reported its first coronavirus cases on March 8, 2020 and the first death on March 18 that year.
Also read: Covid-19: Bangladesh sees 77 deaths, new cases 2,955
PVA bats for suspension of intellectual property rights on Covid jabs
The People's Vaccine Alliance (PVA) in Asia has called on Japan, Singapore and South Korea to support a proposal seeking a temporary suspension of intellectual property rights on Covid-19 vaccines, a move it believes will pave the way for improved access to jabs across the continent.
The 'temporary TRIPS Waiver’ proposal is slated for discussion at the WTO’s general council meeting on April 30.
In its letter, PVA also urged the leaders of the three Asian nations to ensure that pharmaceutical giants and rich country governments voluntarily join the WHO-led Covid-19 Technology Access Pool.
The letter has been signed by 100 organisations, including Actionaid, APCASO, Asia Dalit Rights Forum, Asia Pacific Alliance for Sexual and Reproductive Health and Rights, Asian Peoples Movement on Debt and Development (APMDD, Oxfam international, South Asia Alliance for Poverty Eradication and Fight Inequality Alliance India, according to a release.
Compared to the terrifying speed at which the virus is spreading and mutating, as most recently being seen in India, scaling up global Covid-19 vaccination access and inoculation have been painfully slow, the letter read.
Also read: Bangladesh, China, others call for avoiding vaccine nationalism
"Most of the world’s population, especially in middle- and lower-income countries, lacks access to the vaccine. At the speed with which it is proceeding, it will take decades to vaccinate all who need it.
"The Covid-19 vaccines are owned by big pharmaceutical corporations who are refusing to share the science and technology that could speed up mass production and distribution for the entire planet," it added.
“No single corporation will ever be able to produce enough vaccine doses quickly for everyone who needs it. If history has taught us anything, it is that pharmaceutical corporations create and protect monopolies in order to maximise profits instead of improving public health. We have seen this in the past with vital medicines for illnesses like HIV or cancer that have been priced far too high, out of reach for most people”, said Karyn Kaplan of Asia Catalyst.
"A temporary waiver of World Trade Organization (WTO) intellectual property rules during the COVID-19 pandemic, proposed by South Africa and India and supported by more than 100 WTO member states and numerous health experts worldwide, is a vital, necessary and urgent step to bring an end to this pandemic," the Alliance said.
Also Read: Bangladesh keen to work with China for research, production of Covid vaccine
WTO TRIPS waiver must be combined with ensuring vaccine know-how and technology is shared openly. This can be achieved through the World Health Organization COVID-19 Technology Access Pool.
These actions would expand global manufacturing capacity, unhindered by industry monopolies that are driving the dire supply shortages blocking vaccine access, according to PVA
“When the pharmacy of the world is gasping for breath, keeping monopoly over vaccine science for purpose of profit is immoral, collective failure and self-defeating," said Mustafa Talpur, campaign and advocacy manager of Oxfam international in Asia.
All these roadblocks to control Covid-19 spread are surmountable, the Alliance said.
"The Asia region has a world-class generic pharmaceutical industry with a little more shared technology and know-how, Asia-based companies can quickly support new manufacturing capacity in other countries, thereby reducing the negative impact of COVID and improving response capacity for future pandemics."
Countries in Asia, including China, India, Thailand, and others have demonstrated capacity to produce vaccines.
“Vaccine equity will directly improve health outcomes, as no one is safe until everyone is safe. It is key to the enjoyment of human rights and is equally vital to a comprehensive economic rebuilding out of inequality, poverty and hunger. There is no time to lose! This is an urgent call for a solidaristic, humanitarian and accountable response to save millions of Asian people and their futures”, said Sandeep Chachra, Executive Director of Actionaid Association India.
Covid-19 in Bangladesh: Daily deaths shoot past 100; new cases fall dramatically
After a slight fall for several days, Bangladesh’s daily coronavirus death toll crossed the 100-mark again on Sunday with a sharp fall in new cases.
Fatalities climbed to 11,053 with 101 deaths in the past 24 hours until the morning. The virus also infected 2,922 people, the Directorate General of Health Services (DGHS) said in a handout.
The daily infection rate rose to 13.33 percent from Saturday’s 13.11 percent while the mortality rate remained static at 1.48 percent.
Bangladesh has so far confirmed 745,322 coronavirus cases.
Also read: Border with India to remain shut for 14 days: FM
Between April 16 and 19, the country recorded over 100 deaths, breaking all previous records. The country registered 91, 95 and 98 Covid-related deaths on April 20, 21 and 22 respectively.
On April 23 ad 24, the number fell to 88 and 83.
Bangladesh has so far tested 5,345,501 samples, including 21,922 in the last 24 hours.
Covid-19: Bangladesh records 88 deaths, 3629 new cases
Bangladesh recorded 88 coronavirus-related deaths in the last 24 hours until Friday morning as the country grapples to tackle the second wave of the virus.
The health authorities also reported 3,629 new cases, said the Directorate General of Health Services in a handout.
The coronavirus death toll now stands at 10,869 with the mortality rate slightly rising to 1.47 percent after staying at 1.46 for the last two days.
Meanwhile, the daily infection rate fell to 14 percent from Thursday’s 14.63 percent.
Between April 16 and 19, the country recorded over 100 deaths breaking previous daily records. Bangladesh saw 91, 95 and 98 Covid-related deaths on April 20, 21 and 22 respectively.
Bangladesh reported its first coronavirus cases on March 8 last year and the first death on the 18th of that month.
Also read: Covid-19: Bangladesh sees 98 more deaths, 4014 new infections
Health authorities have so far confirmed 739,703 cases. Among them, 647,674 people - 87.56 percent of all patients – have recovered.